Novo Nordisk joined the many pharmaceutical companies pushing back on government-negotiated drug pricing in the United States.

CMS has released its final rule for Medicare Advantage and Part D for 2026, introducing several regulatory changes aimed at improving care coordination and beneficiary protections. While the rule ...

The Centers for Medicare and Medicaid Services (CMS) finalized an increase of the average benchmark payments to Medicare ...

The Latham drug pricing and market access team invites you to read this digest of recent developments on healthcare reform, the Medicaid Drug ...

Medicare Advantage payments by 5.06%, exceeding projections and benefiting insurers focused on value-based care.

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

U.S. stock futures jump as investors look to recover from recent market routs, global stocks move higher following a down ...

On Wall Street, health insurers helped lead the market after the Centers for Medicare & Medicaid Services announced a ...

Stocks are rising worldwide as some relief flows through financial markets. The S&P 500 climbed 2.4% Tuesday to trim a bit of ...

The big question remains centered on how long Trump will keep his stiff tariffs on other countries, which would raise prices ...